GlycoNexROCO:4168 56 Days Payable is 0.00 as of Dec. 2025. GuruFocus rates ROCO:4168 with a GF Score™ of 56/100 and a GF Value™ of NT$75.12 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 701 Biotechnology companies, GlycoNex ranks worse than 142653.21% on this metric.
GlycoNex's average Accounts Payable for the
three
months ended in Dec. 2025 was NT$0.00 Mil. GlycoNex's Cost of Goods Sold for the
three
months ended in Dec. 2025 was NT$3.55 Mil.
Hence, GlycoNex's Days Payable for the
three
months ended in Dec. 2025 was 0.00.
The historical rank and industry rank for GlycoNex's Days Payable or its related term are showing as below:
ROCO:4168's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 112.84 * Ranked among companies with meaningful Days Payable only.
GlycoNex's Days Payable
stayed the same
from Dec. 2024 (0.00) to Dec. 2025 (0.00).
stayed the same
GlycoNex Days Payable Related Terms
GlycoNex Days Payable Historical Data
* Premium members only.
The historical data trend for GlycoNex's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4168 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, GlycoNex's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlycoNex Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GlycoNex's Days Payable distribution charts can be found below:
* The bar in red indicates where GlycoNex's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
GlycoNex's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlycoNex (ROCO:4168) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on GlycoNex and its competitors. According to the industry distribution chart, GlycoNex ranks #999999 out of 701 companies in the Biotechnology industry.
Is GlycoNex's Days Payable too high?
GlycoNex's current Days Payable is 0.00. Based on the distribution chart, GlycoNex ranks #999999 out of 701 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, GlycoNex has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GlycoNex's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GlycoNex ranks #999999 out of 701 companies for Days Payable. This places GlycoNex in the lower half of its industry. The industry median Days Payable is 112.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on GlycoNex and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlycoNex's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlycoNex stock overvalued right now?
Based on GuruFocus' analysis, GlycoNex (ROCO:4168) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$75.12, compared to a current price of NT$25.20 — trading 66.5% below its estimated fair value. The current Days Payable is 0.00. GlycoNex's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For GlycoNex (ROCO:4168), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlycoNex (ROCO:4168) Overvalued in 2026?
Based on GuruFocus' analysis, GlycoNex stock appears to be undervalued.
The current stock price of NT$25.20 is trading 66.5% below its estimated GF Value™ of NT$75.12.
GuruFocus considers GlycoNex to be Significantly Undervalued.
Key valuation signals for ROCO:4168:
Days Payable: 0.00
GF Value™: NT$75.12 vs. price of NT$25.20 (66.5% below fair value)
No single metric tells the full story. See the ROCO:4168 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlycoNex Inc is a Taiwan-based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has a panel of antibodies that targets various carbohydrate antigens. The antibodies are cloned from hybridoma, engineered to improve stability, and can serve as reagents with applications that include ELISA, Western blot, flow cytometry, and TLC immunostaining. The other services provided by the firm include functional evaluation, antibody research, and antibody engineering. It has two reportable segments: antibody new drug, which derives maximum revenue, and exclusive investment. Geographically, the group derives maximum revenue from Taiwan and the rest from Japan.
56GF Score
Get the complete analysis for ROCO:4168
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4168 has been successfully added to your 
